-
公开(公告)号：US20140141442A1
公开(公告)日：2014-05-22
申请号：US14115643
申请日：2012-05-04
申请人： Luisa Miguel Verdelho Trindade Van Gerven , Hinrich Gronemeyer , Shankara Narayanan Pattabhiraman
发明人： Luisa Miguel Verdelho Trindade Van Gerven , Hinrich Gronemeyer , Shankara Narayanan Pattabhiraman
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6806 , C12Q1/6865 , C12Q2522/101 , C12Q2525/143 , C12Q2535/122 , C12Q2521/131 , C12Q2525/173 , C12Q2531/101
摘要： The present invention provides materials and methods for DNA amplification, in particular linear amplification methods using RNA polymerase. These methods permit high-throughput sequencing of pictogram amounts of DNA and are of use in a range of applications including genome-wide profiling of transcription factors and epigenetic DNA and histone modifications, global transcript profiling, mapping of chromatin conformations, as well as for forensic use and archaeological studies.
摘要翻译： 本发明提供用于DNA扩增的材料和方法，特别是使用RNA聚合酶的线性扩增方法。 这些方法允许象形图量的DNA的高通量测序，并且在一系列应用中使用，包括转录因子和表观遗传学DNA和组蛋白修饰的全基因组谱，全局转录谱分析，染色质构象的映射以及法医学 使用和考古研究。
-
公开(公告)号：US06268173B1
公开(公告)日：2001-07-31
申请号：US08891640
申请日：1997-07-11
IPC分类号： C12N1511
CPC分类号： C07K14/4702
摘要： The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.
摘要翻译： 本发明涉及核受体（NR）转录介体。 更具体地，提供编码转录中介因子-2（TIF2）的分离的核酸分子。 还提供了用于制备TIF2多肽的重组方法，如TIF2抗体。 还提供筛选方法用于鉴定核受体的激活功能AF-2的激动剂和拮抗剂，用于鉴定TIF2的AD1活化域活性的激动剂和拮抗剂，以及用于鉴定TIF2的AD2活化域活性的激动剂和拮抗剂。
-
公开(公告)号：US06624154B1
公开(公告)日：2003-09-23
申请号：US09556675
申请日：2000-04-21
IPC分类号： A01N4500
CPC分类号： A61K45/06
摘要： The invention relates to compositions comprising a retinoid X receptor agonist and an agent capable of activating protein kinase A. The invention also relates to methods of treating hyperproliferative diseases by administering a retinoid X receptor agonist and an agent capable of activating protein kinase A.
摘要翻译： 本发明涉及包含类视黄醇X受体激动剂和能够激活蛋白激酶A的试剂的组合物。本发明还涉及通过施用类视黄醇X受体激动剂和能够激活蛋白激酶A的药剂来治疗过度增殖性疾病的方法。
-
4.发明授权Derivatives of psammaplin A, a method for their synthesis and their uses for the prevention or treatment of cancer 失效psammaplin A的衍生物，其合成方法及其用于预防或治疗癌症的用途公开(公告)号：US08338473B2
公开(公告)日：2012-12-25
申请号：US12528020
申请日：2008-02-28
IPC分类号： A61K31/404 , C07D209/12
CPC分类号： C07D209/30
摘要： Derivatives of psammaplin A responding to formula (I), a method for their synthesis and their use for the preparation of a medicament for preventing and for treating a tumor or a cancer. Formula (I).
摘要翻译： 对于式（I）的psammaplin A的衍生物，其合成方法及其在制备用于预防和治疗肿瘤或癌症的药物中的用途。 式（I）。
-
公开(公告)号：US06861508B2
公开(公告)日：2005-03-01
申请号：US09842256
申请日：2001-04-26
申请人： Pierre Chambon , Hinrich Gronemeyer , Johannes Voegel , Yves Lutz
发明人： Pierre Chambon , Hinrich Gronemeyer , Johannes Voegel , Yves Lutz
CPC分类号： C07K14/4702
摘要： The present invention concerns a nuclear receptor (NR) transcriptional mediator. More specifically, isolated nucleic acid molecules are provided encoding transcriptional intermediary factor-2 (TIF2). Recombinant methods for making TIF2 polypeptides are also provided as are TIF2 antibodies. Screening methods are also provided for identifying agonists and antagonists of the activation function AF-2 of nuclear receptors, for identifying agonists and antagonists of the AD1 activation domain activity of TIF2, and for identifying agonists and antagonists of the AD2 activation domain activity of TIF2.
摘要翻译： 本发明涉及核受体（NR）转录介体。 更具体地，提供编码转录中介因子-2（TIF2）的分离的核酸分子。 还提供了用于制备TIF2多肽的重组方法，如TIF2抗体。 还提供筛选方法用于鉴定核受体的激活功能AF-2的激动剂和拮抗剂，用于鉴定TIF2的AD1活化域活性的激动剂和拮抗剂，以及用于鉴定TIF2的AD2活化域活性的激动剂和拮抗剂。
-
6.发明授权Modified nuclear glucocorticoid receptor, fusion protein, and DNA fragments coding for said receptor and said fusion protein 失效修饰的核糖皮质激素受体，融合蛋白和编码所述受体和所述融合蛋白的DNA片段公开(公告)号：US06699686B1
公开(公告)日：2004-03-02
申请号：US09125491
申请日：1998-08-20
申请人： Jacques Bertrand Brocard , Pierre Henri Chambon , Hinrich Gronemeyer , Daniel Metzger , Jean-Claude Nicolas , Sylvie Roux
发明人： Jacques Bertrand Brocard , Pierre Henri Chambon , Hinrich Gronemeyer , Daniel Metzger , Jean-Claude Nicolas , Sylvie Roux
IPC分类号： C12N1500
CPC分类号： C12N15/90 , A01K2217/05 , A61K38/00 , C07K14/721 , C07K2319/00 , C12N9/00 , C12N15/63
摘要： A DNA fragment coding for a modified nuclear glucocorticoid receptor, particularly one mutated in the region coding for the ligand binding domain, so that receptor activity is more strongly inducible by a synthetic glucocorticoid ligand than by a natural glucocorticoid ligand, is disclosed. A recombination system inducible in mammals by means of a fusion protein produced between a recombinase and the binding domain of the ligand derived from the modified glucocorticoid receptor of which the activity is more strongly inducible by synthetic glucocorticoids than by natural glucocorticoids, is also disclosed.
摘要翻译： 公开了编码修饰的核糖皮质激素受体的DNA片段，特别是在编码配体结合结构域的区域中突变的核糖糖皮质激素受体，使得受体活性比合成的糖皮质激素配体比天然糖皮质激素配体更强地诱导。 还公开了通过在重组酶和衍生自修饰的糖皮质激素受体的配体的结合结构域之间产生的融合蛋白的复合体系，其通过合成糖皮质激素比天然糖皮质激素更强地诱导其活性。
-
7.发明申请Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer 失效Psammaplin A的新型衍生物，其合成方法及其用于预防或治疗癌症的用途公开(公告)号：US20100120885A1
公开(公告)日：2010-05-13
申请号：US12528020
申请日：2008-02-28
IPC分类号： A61K31/404 , C07D209/04 , A61P35/00
CPC分类号： C07D209/30
摘要： Derivatives of psammaplin A responding to formula (I), a method for their synthesis and their use for the preparation of a medicament for preventing and for treating a tumor or a cancer. Formula (I).
摘要翻译： 对于式（I）的psammaplin A的衍生物，其合成方法及其在制备用于预防和治疗肿瘤或癌症的药物中的用途。 式（I）。
-
8.发明授权Therapeutic combinations of RAR antagonists and RXR agonists and use thereof 有权RAR拮抗剂和RXR激动剂的治疗组合及其应用公开(公告)号：US06653322B1
公开(公告)日：2003-11-25
申请号：US09619308
申请日：2000-07-19
IPC分类号： A61K3147
CPC分类号： A61K45/06
摘要： The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR&agr; antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.
摘要翻译： 本发明提供了通过施用有效量的包含至少一种RAR拮抗剂，优选RARalpha拮抗剂的组合物和至少一种RXR激动剂来治疗患有或易患身体障碍的动物，优选人的组合物和方法 。 没有治疗作用的RXR激动剂与RAR拮抗剂的组合允许使用比先前认为有效的更低剂量的RAR拮抗剂; 这种方法避免了用RAR拮抗剂治疗的许多不期望的生理副作用。
-
9.发明授权Therapeutic combinations of RAR antagonists and RXR agonists and use thereof 失效RAR拮抗剂和RXR激动剂的治疗组合及其用途
公开(公告)号：US6130230A
公开(公告)日：2000-10-10
申请号：US919318
申请日：1997-08-28
IPC分类号： C07D215/12 , A61K31/192 , A61K31/47 , A61K45/06 , A61P17/00 , A61P17/02 , A61P17/04 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/02 , A61P43/00 , A01N43/42
CPC分类号： A61K45/06
摘要： The present invention provides compositions and methods for treating an animal, preferably a human, suffering from or predisposed to a physical disorder by administering an effective amount of a composition comprising at least one RAR antagonist, preferably an RAR.alpha. antagonist, and at least one RXR agonist. The combination of an RXR agonist, which has no therapeutic effects alone, with an RAR antagonist allows the use of lower doses of the RAR antagonist than were previously thought to be efficacious; this approach obviates many of the undesirable physiological side-effects of treatment with RAR antagonists.
摘要翻译： 本发明提供了通过施用有效量的包含至少一种RAR拮抗剂，优选RARα拮抗剂和至少一种RXR的组合物来治疗患有或易于发生身体障碍的动物，优选人的组合物和方法 激动剂。 没有治疗作用的RXR激动剂与RAR拮抗剂的组合允许使用比先前认为有效的更低剂量的RAR拮抗剂; 这种方法避免了用RAR拮抗剂治疗的许多不期望的生理副作用。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
